Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KIF11 | P52732 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14450206 | 0.88 | KIF11 (0.30) | KIF11 | |
| SCHEMBL17210648 | 0.88 | KIF11 (0.30) | KIF11 | |
| SCHEMBL3175803 | 0.87 | — | — | |
| SCHEMBL13202552 | 0.86 | — | — | |
| SCHEMBL18744473 | 0.86 | — | — | |
| SCHEMBL10187601 | 0.86 | — | — | |
| SCHEMBL16348115 | 0.86 | — | — | |
| SCHEMBL368863 | 0.86 | ALDH1A1 (0.35) | — | |
| SCHEMBL29300445 | 0.86 | ODC1 (0.35) | — | |
| SCHEMBL26751242 | 0.86 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024016000-A2 | EIF4A INHIBITORS AND USES THEREOF | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2024-01-18 | — | — | WO | disclosed |
| US-20230040208-A1 | ELECTROCHROMIC APERTURE AND MANUFACTURING METHOD THEREFOR, AND LENS MODULE HAVING ELECTROCHROMIC APERTURE | Shenzhen Guangyi Tech Co., Ltd. (CN) | 2023-02-09 | — | — | US | disclosed |
| EP-4092038-A1 | OPIOID AGONIST PEPTIDES AND USES THEREOF | Protagonist Therapeutics, Inc. (US) | 2022-11-23 | — | — | EP | disclosed |
| WO-2022136555-A1 | IMPROVED CD30 TARGETING ANTIBODY DRUG CONJUGATES AND USES THEREOF | LUDWIG-MAXIMILIANS-UNIVERSITAET MUENCHEN (DE) | 2022-06-30 | — | — | WO | disclosed |
| US-10669538-B2 | Templated molecules and methods for using such molecules | NUEVOLUTION A/S (DK) | 2020-06-02 | — | — | US | disclosed |
| US-10308774-B2 | Polycarbonate containing compounds and methods related thereto | VANDERBILT UNIVERSITY (US) | 2019-06-04 | — | — | US | disclosed |
| US-9758671-B2 | Strain-promoted crosslinking of PEG-based hydrogels via copper-free cycloaddition | BECKER MATTHEW (US) | 2017-09-12 | — | — | US | disclosed |
| US-20170198283-A1 | TEMPLATED MOLECULES AND METHODS FOR USING SUCH MOLECULES | NUEVOLUTION A/S (DK) | 2017-07-13 | — | — | US | disclosed |
| US-20170182173-A1 | POLYMER CONJUGATE FOR DELIVERY OF A BIOACTIVE AGENT | POLYACTIVA PTY LTD (AU) | 2017-06-29 | — | — | US | disclosed |
| US-9688980-B2 | Templated molecules and methods for using such molecules | NUEVOLUTION (DK) | 2017-06-27 | — | — | US | disclosed |
| US-20170166710-A1 | Polycarbonate Containing Compounds and Methods Related Thereto | UNIV VANDERBILT (US) | 2017-06-15 | — | — | US | disclosed |
| US-20170119907-A1 | Targeted Therapeutics | MEDIVATION TECHNOLOGIES, INC. (US) | 2017-05-04 | — | — | US | disclosed |
| US-9637592-B2 | Vitamin functionalized gel-forming block copolymers for biomedical applications | INTERNATIONAL BUSINESS MACHINES CORPORATION (US) | 2017-05-02 | — | — | US | disclosed |
| US-20170107255-A1 | APELIN POLYPEPTIDES | AMGEN INC. (US) | 2017-04-20 | — | — | US | disclosed |
| WO-2017019832-A1 | METHODS AND COMPOSITIONS USING REPAIR CELLS AND CATIONIC DYES | MEDIVATION TECHNOLOGIES, INC. (US) | 2017-02-02 | — | — | WO | disclosed |
| WO-2016050210-A1 | MULTIFUNCTIONALIZED POLYETHYLENE GLYCOL DERIVATIVE AND PREPARATION METHOD THEREFOR | 厦门赛诺邦格生物科技有限公司 | 2016-04-07 | — | — | WO | disclosed |
| US-20070031499-A1 | Readily shapeable xerogels having controllably delayed swelling properties | AKINA, INC. | 2007-02-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170166710-A1 | Polycarbonate Containing Compounds and Methods Related Thereto | ERCC5, ERCC1, PPOX | KIF11 3822/4885 |
| US-20070031499-A1 | Readily shapeable xerogels having controllably delayed swelling properties | SMARCA2, SMARCA4, SMARCE1 | KIF11 1297/4885 |
| US-20170107255-A1 | APELIN POLYPEPTIDES | APLNR, FABP3, AP3B1 | KIF11 3108/4885 |
| US-20170182173-A1 | POLYMER CONJUGATE FOR DELIVERY OF A BIOACTIVE AGENT | PTGIS, PTGIR, PGF | KIF11 966/4885 |
| US-10669538-B2 | Templated molecules and methods for using such molecules | ABL1, DHFR, TYMS | KIF11 2340/4885 |
| US-20170119907-A1 | Targeted Therapeutics | ANXA3, ANXA5, ANXA6 | KIF11 532/4885 |
| US-10308774-B2 | Polycarbonate containing compounds and methods related thereto | ERCC5, ERCC1, PPOX | KIF11 3822/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.